On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Establishes Clinical Advisory Board, to Present at Bloom Burton & Co. Health Care Investor Conference

Company: Cybin Inc. (CLXPF)
Category: News

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced the formation of its clinical advisory board. Additions to the board include Maurizio Fava, MD, psychiatrist-in-chief in the Department of Psychiatry at Massachusetts General Hospital, Lynn Marie Morski, MD, Esq., president of the Psychedelic Medicine Association, and Anthony Back, MD, professor in the Department of Medicine and Division of Oncology at the University of Washington. Alex Belser, PhD, Cybin’s chief clinical officer, will chair the clinical advisory board. “We are delighted to welcome three accomplished experts in their respective fields to guide the strategic development of Cybin’s clinical programs,” said Doug Drysdale, Cybin’s chief executive officer. “Together, Drs. Fava, Morski and Back add unparalleled clinical expertise and strengthen our position to advance psychedelic therapeutics. Their insights will be especially valuable as we move our development pipeline through clinical trials.”

In addition, Cybin announced that it will present at the Bloom Burton & Co. Health Care Investor Conference. According to the update, CEO Doug Drysdale is scheduled to present at 2 p.m. ET on Wednesday April 21, 2021. Interested parties should visit https://nnw.fm/RUSkF to register for the event.

To view the full press releases, visit https://nnw.fm/MUCMG and https://nnw.fm/VxApT

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217